Business Context and Reporting Period
This Form 8-K Current Report was filed by Zentalis Pharmaceuticals, Inc. on June 26, 2020, covering events occurring on that date and effective July 1, 2020. The filing addresses Item 5.02 regarding the departure of a director and the appointment of a new director and officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements rather than financial performance.
Material Changes
- Director Resignation: David E. Goel resigned as a member of the Board of Directors, effective July 1, 2020.
- Director Appointment: Kimberly L. Blackwell, M.D., was appointed as a Class I director, effective July 1, 2020.
- Committee Assignments: Dr. Blackwell was appointed to the Audit Committee and the Nominating and Corporate Governance Committee.
Compensation and Governance Details
Dr. Blackwell's compensation package includes:
- Annual Retainers: $40,000 for Board service, $10,000 for Audit Committee service, and $5,000 for Nominating Committee service.
- Equity Grant: An initial award of options to purchase 42,000 shares of common stock.
- Option Terms: Exercise price of $47.80 per share (fair market value on grant date), vesting in 36 substantially equal monthly installments contingent on continued service.
- Indemnification: Dr. Blackwell entered into the Company's standard indemnification agreement for directors and officers.
Investor Verification Checklist
- Verify the effective date of Dr. Goel's resignation and Dr. Blackwell's appointment (July 1, 2020).
- Confirm the vesting schedule and exercise price ($47.80) of the 42,000 option shares granted to Dr. Blackwell.
- Review the total annual cash compensation ($55,000) allocated to Dr. Blackwell for her board and committee roles.
- Check subsequent filings for any changes to the Board composition or committee structures.